Overall market sentiment has been high on Spero Therapeutics Inc (SPRO) stock lately. SPRO receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.
Spero Therapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on SPRO!
What is Stock Sentiment?
In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company.
Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor.
InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon.
The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.
What's Happening With SPRO Stock Today?
Spero Therapeutics Inc (SPRO) stock is up 1.87% while the S&P 500 is down -0.06% as of 9:46 AM on Thursday, Aug 18. SPRO has gained $0.02 from the previous closing price of $1.07 on volume of 35,530 shares. Over the past year the S&P 500 is down -3.97% while SPRO is down -92.04%. SPRO lost -$3.48 per share in the over the last 12 months.
To screen for more stocks like Spero Therapeutics Inc click here.
More About Spero Therapeutics Inc
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Click Here to get the full Stock Report for Spero Therapeutics Inc stock.